Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 4/20 | 0.60 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.60 |
| ▸ | CYP21A2 | P08686 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.39 |
| ▸ | GCGR | P47871 | 2/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14884178 | 0.84 | MAPT (0.58) | CYP17A1CYP11B1CYP21A2LMNAMAPT | |
| SCHEMBL17880388 | 0.84 | MAPT (0.58) | CYP17A1CYP11B1CYP21A2LMNAMAPT | |
| SCHEMBL15805936 | 0.82 | CHRNB4 (0.50) | CYP17A1CYP11B1CYP21A2CHRNB4CHRNA3 | |
| SCHEMBL8964882 | 0.80 | PGR (0.43) | CYP17A1CYP11B1CYP21A2MAPTCHRNB4 | |
| SCHEMBL7503144 | 0.78 | ALDH1A1 (0.48) | CYP17A1CYP11B1CYP21A2CHRNB4CHRNA3 | |
| SCHEMBL9657303 | 0.77 | CYP2A6 (0.54) | CYP17A1CYP11B1LMNAMAPTTP53 | |
| SCHEMBL16284630 | 0.77 | NOTUM (0.52) | CYP17A1CYP11B1CYP21A2LMNAMAPT | |
| Biphenyl SCHEMBL28049848 | 0.77 | NOTUM (0.65) | LMNAMAPTNOTUMMAPK14MAPK13 | |
| SCHEMBL10042442 | 0.77 | ALDH1A1 (0.52) | CYP17A1CYP11B1CYP21A2CHRNB4CHRNA3 | |
| SCHEMBL17922968 | 0.76 | CYP17A1 (1.00) | CYP17A1CYP11B1CYP21A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| US-9725436-B2 | Cytochrome P450 inhibitors and their method of use | CORTENDO AB (PUBL) (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725436-B2 | Cytochrome P450 inhibitors and their method of use | CORTENDO AB (PUBL) (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725436-B2 | Cytochrome P450 inhibitors and their method of use | CORTENDO AB (PUBL) (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160221990-A1 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | HAYFIN SERVICES LLP (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160221990-A1 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | HAYFIN SERVICES LLP (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160221990-A1 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | HAYFIN SERVICES LLP (GB) | 2016-08-04 | — | — | US | disclosed |
| EP-3044210-A2 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | Cortendo AB (publ) (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2414340-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| WO-2010114971-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114971-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | CYP17A1 3197/4885CYP11B1 2064/4885CYP21A2 3689/4885 |
| US-20160221990-A1 | NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE | CYP11B1, CYP11B2, CYP21A2 | CYP17A1 6/4885CYP11B1 1/4885CYP21A2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.